Used in the synthesis of cabazitaxel, a chemotherapy agent primarily employed in the treatment of advanced prostate cancer. This intermediate plays a critical role in enabling the structural modifications necessary to produce the active pharmaceutical ingredient. It allows for efficient semi-synthesis from natural taxane precursors, improving yield and purity during manufacturing. Its application is therefore essential in oncology drug development, particularly for patients who have become resistant to other taxane therapies.